Prioritisation and risk evaluation of medicines in the environment


Start Date
End Date
IMI2 - Call 17
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
4 550 000
EFPIA in kind
5 606 030
6 000
Total Cost
10 162 030


Active ingredients from medicines can get into the environment through a variety of routes, and once there they can prove harmful to wildlife and ecosystems. In the EU, new medicines are required to undergo an environmental risk assessment (ERA). However, so far just a handful of the 1900 or so active pharmaceutical ingredients (APIs) in use have been assessed.

The aim of PREMIER is to deliver a framework for assessing and characterising the environmental risks of APIs. This framework could be used to prioritise and screen older (‘legacy’) APIs that have never been through an ERA. It could also be used to pick up potential environmental risks in new APIs that are still under development.

PREMIER also hopes its work will contribute to greener drug design in general, and help to make environmental data on APIs more visible and accessible to all stakeholders.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Bristol-Myers Squibb Company Corp, Princeton, NJ, United States
  • Eli Lilly And Company LTD, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Institut De Recherches Internationales Servier Iris, Suresnes, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
  • Eidgenoessische Anstalt Fuer Wasserversorgung Abwasserreinigung Und Gewaesserschutz, Duebendorf, Switzerland
  • Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev, München, Germany
  • Goeteborgs Universitet, Gothenburg, Sweden
  • Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy
  • Leuphana Universitat Luneburg, Luneburg, Germany
  • Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
  • Stichting Radboud Universiteit, Nijmegen, Netherlands
  • The European Medicines Agency, Canary Wharf, London, United Kingdom
  • The University Of Exeter, Exeter, United Kingdom
  • University Of York, York, United Kingdom
  • University of Helsinki, University of Helsinki, Helsinki, Finland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • ECOLOGIC INSTITUT gemeinnützige GmbH, Berlin, Germany
  • Ect Oekotoxikologie GMBH, Flörsheim a.M., Germany
  • Simomics Limited, York, United Kingdom
  • Team - It Research SL, Barcelona, Spain
Project coordinator
Ad Ragas
Stichting Radboud Universiteit